Plaque Psoriasis

These data suggest that psoriasis treatment algorithms may benefit younger patients if they implement a step-down rather than step-up approach to biologic use.

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

These findings from the POETYK-PSO long-term extension trial point to a lack of new safety concerns in the first 5 years of using deucravacitinib for psoriasis.

These data highlight deucravacitinib’s impact among patients with psoriasis who are biologic- and apremilast-naive and those with prior histories with these treatments.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

This review of January 2025 in dermatology news highlights new developments in the treatment of conditions such as psoriasis, alopecia areata, and atopic dermatitis.

This literature review points to a variety of research into differences in the diagnosis and treatment of patients with psoriasis and skin of color compared to non-skin of color patients.

These data may provide useful information for additional studies on the pathogenesis and treatments of urticaria-related psoriasis.

In this analysis, investigators explored whether dietary sodium intake was linked with psoriasis and whether any subgroups of patients were more likely to report salt-sensitive psoriasis.

These real-world, 52-week data demonstrate that deucravacitinib is effective for patients in various age brackets, though BMI has a slight impact on its efficacy.

These data highlight current applications of AI and machine learning in aesthetic medicine, looking specifically at studies graded as Level I or II.

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

This analysis is described as the first to identify predictive factors of oral candidiasis in individuals with psoriasis who are treated with bimekizumab.

In this study, investigators pointed to existing resources available for mental health care among those with various skin conditions.

In this analysis, investigators highlighted various disease-related views and experiences dermatologists may wish to consider among Latine patients with psoriasis.

In the inaugural episode of Skin of Color Savvy, Andrew Alexis, MD, MPH, and Shawn Kwatra, MD, discuss diagnosis and management of itch in skin of color.

This study’s investigators examined long-term risk of dementia and Alzheimer’s dementia in patients with psoriasis, highlighting several notable findings.

The field of dermatology saw a wide array of notable developments this year, with highlights including FDA approvals as well as notable clinical trial results.

In this case–control study, investigators identified relevant comorbidities among individuals with bullous pemphigoid before and after their diagnoses.

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

These data resulted from an investigation of the effect of varying image qualities on the diagnostic abilities of a convolutional neural network (CNN) model and clinicians.

The VISIBLE study’s findings indicate that specific strategies may yield more diverse populations in clinical trials for patients with psoriasis and other conditions.

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis.

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.